An amylin analogue attenuates alcohol-related behaviours in various animal models of alcohol use disorder.


Journal

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907

Informations de publication

Date de publication:
05 2019
Historique:
received: 05 10 2018
accepted: 16 01 2019
revised: 15 01 2019
pubmed: 3 2 2019
medline: 21 12 2019
entrez: 3 2 2019
Statut: ppublish

Résumé

Recent findings have identified salmon calcitonin (sCT), an amylin receptor agonist and analogue of endogenous amylin, as a potential regulator of alcohol-induced activation of the mesolimbic dopamine system and alcohol consumption. Providing that the role of amylin signalling in alcohol-related behaviours remains unknown, the present experiments investigate the effect of sCT on these behaviours and the mechanisms involved. We showed that repeated sCT administration decreased alcohol and food intake in outbred rats. Moreover, single administration of the potent amylin receptor antagonist, AC187, increased short-term alcohol intake in outbred alcohol-consuming rats, but did not affect food intake. Acute administration of sCT prevented relapse-like drinking in the "alcohol deprivation effect" model in outbred alcohol-experienced rats. Additionally, acute sCT administration reduced operant oral alcohol self-administration (under the fixed ratio 4 schedule of reinforcement) in selectively bred Sardinian alcohol-preferring rats, while it did not alter operant self-administration (under the progressive ratio schedule of reinforcement) of a highly palatable chocolate-flavoured beverage in outbred rats. Lastly, we identified differential amylin receptor expression in high compared to low alcohol-consuming rats, as reflected by decreased calcitonin receptor and increased receptor activity modifying protein 1 expression in the nucleus accumbens (NAc) of high consumers. Collectively, our data suggest that amylin signalling, especially in the NAc, may contribute to reduction of various alcohol-related behaviours.

Identifiants

pubmed: 30710109
doi: 10.1038/s41386-019-0323-x
pii: 10.1038/s41386-019-0323-x
pmc: PMC6461824
doi:

Substances chimiques

Amylin Receptor Agonists 0
Peptide Fragments 0
Receptors, Islet Amyloid Polypeptide 0
AC 187 161902-50-7
salmon calcitonin 7SFC6U2VI5
Calcitonin 9007-12-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1093-1102

Subventions

Organisme : Vetenskapsrådet (Swedish Research Council)
ID : 2015-03219
Pays : International
Organisme : Sahlgrenska Universitetssjukhuset (Sahlgrenska University Hospital)
ID : 148251
Pays : International

Références

Eur J Pharmacol. 1994 Sep 1;262(1-2):133-41
pubmed: 7813564
PLoS One. 2013 Aug 20;8(8):e71284
pubmed: 23977009
Neuropsychopharmacology. 2014 Dec;39(13):3009-17
pubmed: 24957819
Int J Neuropsychopharmacol. 1999 Sep;2(3):173-179
pubmed: 11281986
Eur J Neurosci. 2014 Oct;40(7):3055-66
pubmed: 25040689
PLoS One. 2013 Apr 08;8(4):e61242
pubmed: 23579732
Mol Pharmacol. 2005 May;67(5):1655-65
pubmed: 15692146
Neuropsychopharmacology. 2013 Aug;38(9):1685-97
pubmed: 23474592
Neuron. 2002 Oct 10;36(2):285-98
pubmed: 12383782
Int J Obes Relat Metab Disord. 2001 Jul;25(7):1005-11
pubmed: 11443499
Eur J Neurosci. 2001 Aug;14(4):618-28
pubmed: 11556887
Front Neurosci. 2015 Nov 05;9:424
pubmed: 26594143
PLoS One. 2016 May 03;11(5):e0154477
pubmed: 27139195
Treat Endocrinol. 2004;3(2):117-32
pubmed: 15743107
Physiol Behav. 2004 May;81(3):481-8
pubmed: 15135020
Physiol Behav. 2010 Jul 14;100(5):511-8
pubmed: 20226802
Obes Res. 2004 Apr;12(4):661-8
pubmed: 15090634
Trends Pharmacol Sci. 1997 Feb;18(2):54-9
pubmed: 9090311
Am J Physiol Regul Integr Comp Physiol. 2007 Nov;293(5):R1855-63
pubmed: 17855496
Front Neurosci. 2014 Sep 18;8:288
pubmed: 25278825
Pharmacol Biochem Behav. 1986 May;24(5):1203-7
pubmed: 3725826
Neuroscience. 2011 Sep 29;192:500-6
pubmed: 21699961
Pharmacol Rev. 2015 Jul;67(3):564-600
pubmed: 26071095
Physiol Behav. 1995 Dec;58(6):1197-202
pubmed: 8623020
Diabetes Obes Metab. 2011 Oct;13(10):911-20
pubmed: 21615667
PLoS One. 2013 Jul 16;8(7):e69010
pubmed: 23874851
CNS Drugs. 2014 Oct;28(10):875-86
pubmed: 24958205
J Physiol. 2002 Jun 15;541(Pt 3):1041-8
pubmed: 12068061
Drug Alcohol Depend. 2011 Sep 1;117(2-3):126-31
pubmed: 21310553
Peptides. 1999;20(3):379-82
pubmed: 10447097
Drug Alcohol Depend. 2017 Nov 1;180:68-75
pubmed: 28881319
Am J Physiol Endocrinol Metab. 2015 Jun 15;308(12):E1116-22
pubmed: 25898952
Alcohol Res Health. 2000;24(2):124-31
pubmed: 11199279
Handb Exp Pharmacol. 2012;(209):231-50
pubmed: 22249817
Neuropsychopharmacology. 2015 Jan;40(2):372-85
pubmed: 25035079
Curr Pharm Des. 2011;17(14):1323-32
pubmed: 21524263
Physiol Rev. 2014 Oct;94(4):1099-142
pubmed: 25287861
Adv Pharmacol. 2005;52:47-65
pubmed: 16492540
Curr Drug Abuse Rev. 2008 Nov;1(3):280-91
pubmed: 19630726
Addict Biol. 2012 Nov;17(6):956-63
pubmed: 21790898
Neuroscience. 1994 Sep;62(2):553-67
pubmed: 7830897
Calcif Tissue Int. 1991;49 Suppl 2:S7-8
pubmed: 1933617
Endocrinology. 2001 Nov;142(11):5035
pubmed: 11606473
Am J Physiol Regul Integr Comp Physiol. 2004 Sep;287(3):R568-74
pubmed: 15130879
Am J Physiol Regul Integr Comp Physiol. 2001 Jun;280(6):R1697-703
pubmed: 11353673
Philos Trans R Soc Lond B Biol Sci. 2006 Jul 29;361(1471):1219-35
pubmed: 16815800
Biol Psychiatry. 2017 Dec 1;82(11):828-838
pubmed: 28237459
BioDrugs. 2008;22(6):375-86
pubmed: 18998755
Addict Biol. 2016 Mar;21(2):422-37
pubmed: 26303264
Am J Physiol Regul Integr Comp Physiol. 2007 Nov;293(5):R1798-808
pubmed: 17761508
Addict Biol. 2019 May;24(3):388-402
pubmed: 29405517
Peptides. 2000 Feb;21(2):233-8
pubmed: 10764950
J Pharmacol Exp Ther. 1994 Aug;270(2):779-87
pubmed: 8071870
Pharmacol Biochem Behav. 1997 Jan;56(1):123-9
pubmed: 8981619
Physiol Rev. 2011 Jul;91(3):795-826
pubmed: 21742788
Psychopharmacology (Berl). 2010 Sep;211(4):415-22
pubmed: 20559820
Obes Res. 2002 Oct;10(10):1087-91
pubmed: 12376591
Addict Biol. 2006 Sep;11(3-4):324-38
pubmed: 16961762
Brain Res. 1995 Sep 4;690(2):249-53
pubmed: 8535845
Can J Physiol Pharmacol. 1995 Jul;73(7):1025-9
pubmed: 8846395

Auteurs

Aimilia Lydia Kalafateli (AL)

Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

Daniel Vallöf (D)

Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

Giancarlo Colombo (G)

Neuroscience Institute, Section of Cagliari, National Research Council of Italy, Monserrato, CA, Italy.

Irene Lorrai (I)

Neuroscience Institute, Section of Cagliari, National Research Council of Italy, Monserrato, CA, Italy.

Paola Maccioni (P)

Neuroscience Institute, Section of Cagliari, National Research Council of Italy, Monserrato, CA, Italy.

Elisabet Jerlhag (E)

Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. Elisabet.Jerlhag@pharm.gu.se.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH